Is the AbbVie website a product specific site?
You are about to leave the AbbVie website. The product-specific site Internet site that you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals that are not approved in other countries or region.
Are there any AbbVie drugs that are unapproved?
Safety and efficacy have not been established for any of these drugs for the uses being studied. AbbVie in no way intends to recommend or imply that these drugs should be used for unapproved uses. Venetoclax (ABT-199/GDC-0199) is a selective, orally bioavailable small-molecule BCL-2 inhibitor. 1
What makes AbbVie so important to the world?
By putting patients first, we explore new medical innovations and ways to enhance access AbbVie combines advanced science, expertise and passion to solve the world’s most serious health issues and have a remarkable impact on people’s lives
What are the risks of using AbbVie data?
AbbVie assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.
What kind of research is AbbVie doing with Synlogic?
Synlogic is a synthetic biology company built on research from the labs of James Collins and Tim Lu at MIT. As part of the collaboration, AbbVie is getting worldwide rights to Synlogic’s probiotic -based technology for treating inflammatory bowel disease, and the research teams will focus on Crohn’s disease and ulcerative colitis.
When did AbbVie license Enhanze technology to Halozyme?
On June 3, 2015, AbbVie and Halozyme Therapeutics announced that they had entered into a global collaboration and licensing agreement to develop and commercialize products that combine AbbVie’s treatments and Halozyme’s ENHANZE drug-delivery technology, this was terminated in November 2016.